University of South Florida-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study

    Brain, Vol. 147, Núm. 8, pp. 2652-2667

2021

  1. Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk

    Diabetologia, Vol. 64, Núm. 4, pp. 826-835

2019

  1. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations

    Parkinsonism and Related Disorders, Vol. 60, pp. 138-145

2016

  1. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

    Movement Disorders, Vol. 31, Núm. 5, pp. 742-747

2014

  1. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

    Movement Disorders, Vol. 29, Núm. 4, pp. 470-478

  2. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicenter, randomized double-masked, placebo-controlled trials

    Diabetes Technology and Therapeutics

  3. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

    Nature Genetics, Vol. 46, Núm. 9, pp. 989-993

2013

  1. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials

    The Lancet, Vol. 381, Núm. 9881, pp. 1905-1915

2007

  1. The TRIGR trial: Testing the potential link between weaning diet and type 1 diabetes

    Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, Vol. 7, Núm. 3, pp. 251-263